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Abstract
Introduction Despite advances in treatment, infective endo-
carditis (IE) still ranks amongst the most lethal infectious
diseases. We sought to determine prognostic factors in gen-
eral hospitals in the Netherlands as research in this setting
is scarce.
Results Between 2004 and 2011, we identified 216 cases
of IE, 30.1 % of which were prosthetic valve IE. This leads
to an annual incidence of IE of 5.7 new cases per 100,000
persons per year. Women were less likely to undergo sur-
gical intervention (OR = 1.96, 95 % CI 1.06–3.61, p =
0.031). Also, ageing was an independent prognostic factor
for not receiving surgery in a multivariate analysis (annual
OR = 1.04, 95 % CI 1.02–1.06, p < 0.001). Female sex
was a prognostic factor for mortality (OR = 2.35, 95 % CI
1.29–4.28, p = 0.005). Age was also an independent prog-
nostic factor for mortality (OR = 1.05, 95% CI 1.03–1.08,
p < 0.001). Conservative treatment was a prognostic factor
for mortality (OR = 3.39, 95 % CI 1.80–6.38, p < 0.001)
whereas surgical intervention was an independent prognos-
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tic factor for adverse events (OR = 3.03, 95% CI 1.64–5.55,
p < 0.001). Staphylococcus aureus was an independent
prognostic factor for adverse events (OR = 2.05, 95 % CI
1.10–3.84, p = 0.024) but not for mortality.
Conclusion This study shows that endocarditis in general
hospitals has a high rate of morbidity and mortality. Even
when treated, it ranks as one of the most lethal infectious
diseases in the Netherlands, especially in women and the
elderly.
Keywords Endocarditis · Survival analysis · Hospitals,
general · Mortality · Morbidity · Staphylococcus aureus
Introduction
Since William Osler first described ‘malignant endocarditis’
in 1885, there has been an evolution in the pathophysiology
and treatment of this rare but often lethal disease [1–4].
A decreased incidence of rheumatic heart valve disease
but increased incidence of degenerative heart valve disease
has changed the demographics of patients affected with in-
fective endocarditis (IE) in the Western world [5–8]. In-
terestingly, in the Netherlands, due to lower numbers of
intravenous drug users, the frequency of right-sided endo-
carditis has notably dropped [9]. At the same time, the
worldwide rise in methicillin-resistant Staphylococcus au-
reus (MRSA) has augmented MRSA-related IE [10–14].
Furthermore, there has been a substantial increase in the
use of prosthetic heart valves, both mechanical and bio-
logical [15]. Also, the increased use of devices such as
pacemakers and implantable cardiac defibrillators is posing
new challenges [10].
Previous studies in the Netherlands that assess the treat-
ment of IE enrolled patients who were treated in a ter-
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Fig. 1 Annual distribution of new IE cases per year
tiary hospital [16–19]. One can hypothesise that patient de-
mographics and outcome between a general and a tertiary
hospital differ due to patient selection and available treat-
ment modalities. Our experience is that an IE population
in a tertiary centre will largely consist of patients eligible
for surgical intervention or those who have undergone an
operation. There will be very few patients who receive con-
servative treatment. A general hospital’s population, on the
other hand, will mainly consist of patients who receive con-
servative treatment and a few patients recovering from an
earlier operation. However, studies focussing on IE in gen-
eral hospitals are scarce [20]. The primary aim of our study
is to describe the demographics and identify the prognostic
factors of IE in general hospitals in the Netherlands.
Furthermore, a changing insight into the demography
and prophylaxis of IE [16, 17] has led to the development
of the 2009 European Society of Cardiology (ESC) guide-
line on prevention, diagnosis and treatment of IE [21]. The
result of this guideline has been a less strict use of pro-
phylaxis. The secondary aim of this study is to evaluate
implementation of the revised guideline on the prevention
of IE in our patient population [21].
Material and Methods
A multicentre retrospective cohort study was performed in
three general hospitals in the Netherlands (Spaarne [former
Kennemer] Gasthuis Haarlem, Gelre Hospital Apeldoorn,
Gelre Hospital Zutphen). Data collection was performed
between 2012 and 2013. Patients treated for IE were iden-
tified using the Dutch national in-hospital insurance registry
(Diagnose Behandel Combinatie). All patients treated for
definite or possible IE between 2004 and 2011 were in-
cluded. All patient charts, echocardiogram reports and mi-
crobiology reports were reviewed. Median follow-up was
4.2 years (0.3–8.0). The modified Duke criteria were ap-
plied to identify patients with definite IE [21]. Patients
with possible IE, according to the modified Duke criteria,
but treated as definite IE were also included. Patients with
native and/or prosthetic valve IE were enrolled as well as
pacemaker device and/or lead infection. The treating car-
diologist evaluated the transthoracic and transoesophageal
echocardiograms and identified the valve or lead vegeta-
tion. MRSA was defined as such after consultation with
a microbiologist or when another antibiotic was used than
the first-line therapy according to the local guidelines.
Mortality was defined as all-cause mortality within the
follow-up period. Adverse events were defined as IE-re-
lated adverse events during hospitalisation requiring med-
ical intervention or prolonging hospital stay. The adverse
events included were infarction (including stroke and pe-
ripheral septic emboli), bleeding, recurrent endocarditis,
tachyarrhythmias and abscess formation at any location.
Statistical analysis was performed using SPSS (I.B.M.
Armonk, NY, USA) and R (www.r-project.org). Student’s
t test was used for continuous variables and Fisher’s exact
test/Chi-square test for categorical variables. Multivariate
logistic regression analyses were performed to determine
independent risk factors for mortality and morbidity. A two-
tailed p value of p < 0.05 or less was considered statistically
significant.
As this is a retrospective study, approval of the local
ethics committee was not needed.
Results
Patient characteristics
Between 2004 and 2011, we identified 216 cases of IE
(Fig. 1). Based on the three general hospitals and the per-
hospital catchment area, this would amount to an annual
incidence of IE of 5.7 new cases per 100,000 persons per
year [22, 23]. The mean age at the time of the diagno-
sis was 67.5 years (22–97). Men were more affected than
women: 62.5 % versus 37.5 %. Definite IE was diagnosed
in 82.8 % of the patients. Transthoracic echocardiogram
confirmed the diagnosis in 19.4 % of the cases and transoe-
sophageal echocardiogram in 74.1 %. In 6.5 % no vegeta-
tion was visible. A total of 44 % of the population did not
have a predisposing risk factor for IE.
Affected valves
One-third of the patients had prosthetic valve IE (30.1 %).
A pacemaker device lead located at the right side of the
heart was affected in 17 cases. In these 17 cases a left-
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Tab. 1 Prognostic factors for conservative treatment, multivariate analysis
Female sex OR = 1.96, 95 % CI 1.06–3.61, p = 0.031
Age (per life year) OR = 1.04, 95 % CI 1.02–1.06, p < 0.001
Tab. 2 Prognostic factors for mortality, multivariate analysis
Age (per life year) OR = 1.05, 95% CI 1.03–1.08, p < 0.001
Female sex OR = 2.35, 95 % CI 1.29–4.28, p = 0.005
Conservative treatment OR = 3.39, 95 % CI 1.80–6.38, p < 0.001
Tab. 3 Prognostic factors for adverse events, multivariate analysis
Staphylococcus aureus infection OR = 2.05, 95 % CI 1.10–3.84, p = 0.024
Surgical treatment OR = 3.03, 95% CI 1.64–5.55, p < 0.001
sided heart valve was also involved in 2 patients. Only
10 patients had tricuspid or pulmonary valve IE only, none
of which were related to a pacemaker lead infection.
Microbiology
Positive blood cultures were found in 90.7 % of the pa-
tients. A total of 30.1 % of all patients had Staphylococcus
aureus in 1 or more blood cultures, making it the most
prevalent microorganism. There was only 1 patient with
a MRSA positive culture. A bacterial access location was
found in 115/216 (53.2 %) of the patients. The most preva-
lent access locations were oropharyngeal (30/115, 26.0 %)
cutaneous (23/115 20.0 %), urinary tract (12/115 10.4 %)
and the colon (10/115, 8.7 %). There were only 2 patients
with intravenous drug use as a cause of their IE.
Surgical versus conservative treatment
A total of 84 (38.9 %) patients were accepted for surgical
intervention. Eight underwent only pacemaker lead extrac-
tion. S. aureus endocarditis or prosthetic valve IE were
not independent prognostic factors for receiving surgical
intervention. Women were less likely to undergo a surgical
intervention (OR = 1.96, 95 % CI 1.06–3.61, p = 0.031).
Also, ageing was an independent prognostic factor for not
receiving surgery in a multivariate analysis (annual OR =
1.04, 95 % CI 1.02–1.06, p < 0.001) (Tab. 1).
Outcomes
All-cause mortality was 36.1 %. Mortality in women was
significantly higher than in men (49.3 % versus 28.2 %, p
= 0.002). Female sex was an independent prognostic factor
for mortality (OR = 2.35, 95 % CI 1.29–4.28, p = 0.005).
The mean age at time of death was 76 years while the mean
age for the surviving patients was 65 (p < 0.001, 95 % CI
4.66–12.15). Age was an independent prognostic factor for
mortality as well (OR = 1.05, 95% CI 1.03–1.08, p < 0.001)
(Tab. 2). Age and gender were not independent prognostic
factors for adverse events.
S. aureus was an independent prognostic factor for ad-
verse events (OR = 2.05, 95 % CI 1.10–3.84, p = 0.024)
but not for mortality (OR = 1.90, 95 % CI 0.99–3.66, p =
0.054) (Tab. 3).
Mortality was higher in prosthetic valve IE 42/65
(66.2 %) when compared with native valve IE 56/151
(37.0 %) (p < 0.001). In a multivariate analysis between
prosthetic valve IE versus native valve IE there were no sig-
nificant differences in mortality and adverse events. Mor-
tality was higher in the conservative treatment group 62/132
(46.9 %) when compared with the surgical group; 16/84
(19.0 %) (p = <0.001). Conservative treatment was an in-
dependent prognostic factor for mortality (OR = 3.39, 95 %
CI 1.80–6.38, p < 0.001) (Tab. 2). The incidence of adverse
events was higher in the surgical group (62/84, 73.8 %) than
in the conservative treatment group (64/132, 48.4 %). Sur-
gical intervention was an independent prognostic factor for
adverse events (OR = 3.03, 95% CI 1.64–5.55, p < 0.001)
(Tab. 3).
Introduction of new ESC guideline
Our study includes 126 patients before and 90 patients after
the introduction of the new ESC guideline on the preven-
tion, diagnosis and treatment of IE. Amongst these patients,
we did not find an evident increase in incidence of IE before
and after the introduction of the new ESC guideline. Com-
paring the population before and after introduction of the
new guideline there was no difference in mortality (OR =
1.82, 95 % CI 0.97–3.50, p = 0.0665) or the number of ad-
verse events (OR = 0.60, 95 % CI 0.34–1.04, p = 0.0698).
There was no significant difference in the chance of receiv-
ing a surgical intervention before and after the introduction
of the ESC guideline. Of the whole cohort only 1/216
(0.46 %) patient had received prophylaxis.
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Discussion
To our knowledge this is the first multicentre retrospective
cohort study on IE performed only in general hospitals in
the Netherlands. This research shows that overall mortal-
ity associated with IE is higher than in other recent studies
[16–19]. As there is no selection bias due to referral for
possible surgical intervention we believe that, despite im-
provements in treatment, mortality still remains high and
makes IE one of the most lethal infectious diseases in the
Western world.
Although this study focuses on all-cause mortality it does
show there might be an underestimation of IE-related mor-
tality based on the rates from previous studies [16–19]. As
stated in our introduction, patient demographics and out-
comes between general hospitals and tertiary hospitals dif-
fer: more patients who are not eligible for operation will
remain in a general hospital and will receive conservative
treatment. Our study shows that conservative treatment is
related to a higher mortality, hence a possible explanation
for the high overall mortality rates. Female sex is a prog-
nostic factor for mortality but not for adverse events. Our
study shows that women are less likely to receive surgical
intervention. As this study also shows that surgical inter-
vention has a better prognosis, this may be an explanation
why mortality in women is higher than in men. Earlier sur-
gical intervention may be the key to improving survival in
women with IE. Previous studies endorse our results, stat-
ing that surgical intervention improves survival and adverse
event-free interval [2, 24].
Prosthetic valve IE has a higher mortality when com-
pared with native valve IE, but our study does not show
a difference in adverse events between prosthetic and native
valves. This might be explained by the population in gen-
eral hospitals in which patients will not be eligible for surgi-
cal intervention due to existing comorbidities and therefore
will not receive surgery. As surgery is no longer an option,
they may have entered a palliative setting in which there
was no further recording of adverse events and as such
a possible loss to follow-up. A similar mechanism may ex-
plain the difference in mortality and adverse events between
surgical treatment and conservative treatment. Patients who
received surgery possibly had a better preoperative physi-
cal condition and therefore had higher survival rates. As
the monitoring postoperatively might be better when com-
pared with conservative treatment, there could have been an
earlier detection of adverse events. Patients who received
conservative treatment may have entered a palliative setting
in which there was no further recording of adverse events.
S. aureus IE increases the risk of disease-related mor-
bidity. As S. aureus spread is increasing in the population,
this is a growing concern and may lead to a higher disease
burden in the future. Fortunately, MRSA does not yet pose
a significant problem in IE. The fact that MRSA has hardly
penetrated the endocarditis population does not mean that
it will not do so in the future. In a number of cases in
our cohort no organism was cultured. This might be due
to antibiotics having been started by a general practitioner
prior to presentation in a hospital.
Although we do not see a difference in the number of
new cases, mortality, adverse events and number of surgical
interventions between the era before and after the introduc-
tion of the new ESC guidelines, this may be due to the
small sample size. Other recent studies have shown an
increase in incidence in IE related to the introduction of
the National Institute of Clinical Excellence 2008 guideline
and the America College of Cardiologist/American Heart
Association 2007 guidelines [25, 26].We expect the Dutch
population to be similar to the ones described by Pant et al.
and Dayer et al. and think a similar change in the prevalence
of endocarditis might have taken place in the Netherlands
since the introduction of the guidelines.
The study design, a multicentre retrospective cohort
study, is a limitation to this study. The difference in time
of follow-up of the patients included varies widely and as
such might have influenced the numbers for mortality and
adverse effects.
Conclusion
This research shows that the endocarditis in general hospi-
tals has a high rate of morbidity and mortality. Even when
treated it ranks as one of the most lethal infectious diseases
in the Netherlands, especially in women and the elderly.
Further investigation is needed to determine optimal treat-
ment and the effectiveness of the new ESC Guideline on
the prevention, diagnosis and treatment of infective endo-
carditis.
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